Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.47 |
| ▸ | RARB | P10826 | 3/20 | 0.46 |
| ▸ | GSTA1 | P08263 | 2/20 | 0.46 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2871239 | 1.00 | TP53 (0.49) | TP53TSHRPLA2G4BS1PR1S1PR3 | |
| SCHEMBL2859727 | 0.97 | GSTA1 (0.45) | TP53TSHRPLA2G4BS1PR1S1PR3 | |
| SCHEMBL2867926 | 0.92 | PLK1 (0.49) | TSHRGSTA1GSTP1 | |
| SCHEMBL2872134 | 0.87 | MAPT (0.47) | TP53 | |
| SCHEMBL2861309 | 0.87 | THRA (0.43) | RARBGSTA1GSTP1 | |
| SCHEMBL2871495 | 0.86 | GAA (0.42) | GSTA1GSTP1 | |
| SCHEMBL2866977 | 0.86 | S1PR1 (0.47) | TP53TSHRPLA2G4BS1PR1S1PR3 | |
| SCHEMBL2868223 | 0.85 | THRA (0.50) | TP53TSHRPLA2G4BS1PR1S1PR3 | |
| SCHEMBL2871447 | 0.85 | THRA (0.50) | TP53TSHRPLA2G4BS1PR1S1PR3 | |
| SCHEMBL2874047 | 0.84 | THRA (0.49) | TP53TSHRPLA2G4BS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691898-B2 | Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1813620-A1 | PHOSPHONIC ACID DERIVATIVE AND THERAPEUTIC AGENT FOR DISEASE IN WHICH HIGH PHOSPHATE LEVEL IN BLOOD PARTICIPATES | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | NR0B1, NR0B2, PTH1R | TP53 2526/4885TSHR 294/4885PLA2G4B 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.